Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs KeyCorp (KEY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs KeyCorp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $300.02 (market cap $39.89B), while KeyCorp trades at $23.33 (market cap $25.15B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and KeyCorp pays a 3.52% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | KEY | |
|---|---|---|
Market Cap | $39.89B | $25.15B |
Sector | Health | Financials |
52-Week High | $491.22 | $23.43 |
52-Week Low | $278.09 | $16.78 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
KeyCorp (KEY) trades at $23.30, up 0.87% on the day, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.42. Revenue rebounded to $7.29 billion in 2025, driving net income to $1.83 billion. Analyst consensus is strongly positive, with a $29.32 price target representing significant upside. Recent news highlights a new $3 billion share buyback program and innovations in business fraud protection.
The outlook for KEY is favorable, supported by earnings momentum, shareholder returns, and analyst optimism. Key opportunities include continued earnings beats and capital return initiatives. Risks involve volatile cash flows, with net cash flow negative in 2025 and 2026, and sensitivity to interest rate changes affecting bank profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
